Eculizumab showed sustained activity and tolerability through 3 years for generalized myasthenia gravis.
American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting (AANEM)
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Issues Complete Response Letter for Spinocerebellar Ataxia Agent Troriluzole
2
Dental Caries and Periodontal Disease Increase Ischemic Stroke Risk, Study Shows
3
Understanding the Global Impact of the Honolulu Asian Aging Study: George W. Ross, MD
4
FDA Feedback Provides Clarity for Phase 3 Trial of Neflamapimod in Dementia With Lewy Bodies
5
